Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PLX-R18 in Incomplete Hematopoietic Recovery Post-HCT
NCT03002519Phase 1Completed
- Sponsor
- Pluri Inc.
- Start
- Feb 2017
- Primary completion
- Sep 2021
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of human placenta mesenchymal stromal cells, sponsored by Pluri Inc. Primary endpoints: Emergent Adverse Events at 1 year, Safety laboratory values at 1 year and 2 more. Started Feb 2017; status: completed.
02
Drugs
human placenta mesenchymal stromal cells
Beyond the preview
Go deeper on NCT03002519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002519.